n (Life Sciences & Allied Applications / Biology) the mimicking of life using imitation biological systems


Simon Cartmell


With 30 years’ pharmaceutical, biotech and medtech experience gained in commercial, product development, supply chain, strategic leadership and corporate executive roles, Simon is a serial entrepreneur in early stage healthcare businesses. As CEO of ApaTech Ltd, a QMUL spinout, he developed a world leader in orthobiologics prior to its sale to Baxter for $330m in March 2010.Prior to joining ApaTech in 2004 Simon was a Main Board Director of Celltech Group plc, serving as CEO, Celltech Pharmaceuticals, prior to which he served as COO of Vanguard Medica (later Vernalis plc). The early part of his career was spent at Glaxo/Glaxo Wellcome plc in a series of senior UK and international commercial, supply chain and strategic development leadership roles.He is currently a Non-Executive Director of Phase4 Ventures and ReNeuron plc, an advisor to the MTI/University of Manchester Premier Fund and part-time CEO of Calon Cardio-Technology Ltd.


Dr Geoffrey Vernon


Geoffrey is a member of the Royal Pharmaceutical Society and a Fellow of the Institute of Directors. He has extensive corporate governance experience in private and public companies and was accredited in 1999 as the first Director in the UK with the professional qualification of Chartered Director. Over the last fifteen years he has established credibility with European and US investment bankers, analysts and financial institutions. He has worked in industry, public and private companies, venture capital and has exposure to fund management.


Dr Nigel Pitchford


Nigel joined Imperial Innovations as Managing Director of Healthcare in January 2012, and became Chief Investment Officer of Imperial Innovations Group in October 2013. He was previously a Partner at DFJ Esprit, and prior to that spent 12 years at 3i, becoming a Partner in 2006, and ultimately leading the venture team’s healthcare activities across Europe and the US. He has also served on the boards of EUSA Pharma and HBI. Nigel is currently a non-executive director on the boards of Oxford Immunotec, Polytherics and E3Bio.


Alan O’Connell


Alan is a Partner at Seroba Life Sciences. Prior to joining Seroba Life Sciences, Alan worked in a variety of product development and business development roles at Elan Corporation (Dublin), American Biogenetic Sciences, Inc. (New York), and the Medicines Control Agency (London). His previous venture capital experience was gained at Estée Lauder Investments (New York) and he still sits on the Lauder Scientific Advisory Board. In addition to Veryan, Alan sits on the boards of Ario Pharma, Opsona, Crescent Diagnostics and Heart Metabolics.


Jeffrey B. Jump

Non-Executive Director

Jeff has nearly 30 years’ experience of the medical device industry. He is currently President of interventional cardiology specialists Biosensors, a company with which he has held a succession of senior management roles since 2003. He is also a non-Executive Director of several start-up medical device companies. Over the course of his career Jeff has held senior management roles with Xitact Medical Simulation, Embol-X, Alliance Medical Technologies, Cardio Thoracic Systems, Haemonetics S.A. and Pfizer Hospital Products Group.


Chas Taylor

CEO, Executive Director

Chas has over 20 years’ experience in the medical device industry. He has been involved in successful medical device start-up companies since 1996. He co-founded embolic filter and carotid stent specialists MedNova which was acquired by Abbott in 2005. Before this he worked with CR Bard for twelve years in various sales, marketing and general management roles. During this time he was based in the USA for eight years in senior positions including Vice-President for Bard Cardiovascular.


Paul Gilson

CSO, Executive Director

Paul also has over 20 years’ experience in the medical device industry. He was a co-founder and General Manager of MedNova and was responsible for the development of innovative carotid technologies. Prior to his experience in start-up companies he held a number of senior roles in Operations, Development and R&D. He was Director of R&D for Bard Cardiology where he developed numerous cardiovascular devices. He is the holder of more than 20 patents for biomaterials and cardiovascular products.